DERWENT-ACC-NO: 1998-035947

DERWENT-WEEK: 199804

COPYRIGHT 2009 DERWENT INFORMATION LTD

TITLE: Oral liquid agent for treating cold symptoms

contains

Kakkon-To extract and Stevia Rebaudiana

Bertoni,

Compositae

INVENTOR: OKUDAIRA I; TSUNODA K

PATENT-ASSIGNEE: TAISHO PHARM CO LTD[TAIS]

PRIORITY-DATA: 1996JP-100789 (April 23, 1996)

PATENT-FAMILY:

PUB-NO PUB-DATE LANGUAGE

JP 09286735 A November 4, 1997 JA

APPLICATION-DATA:

PUB-NO APPL-DESCRIPTOR APPL-NO

APPL-DATE

JP 09286735A N/A 1996JP-100789

April 23, 1996

INT-CL-CURRENT:

TYPE IPC DATE
CIPP A61K9/08 20060101
CIPS A61K36/00 20060101
CIPS A61K47/26 20060101
CIPS A61P11/00 20060101
CIPS A61P3/00 20060101

ABSTRACTED-PUB-NO: JP 09286735 A

BASIC-ABSTRACT:

Oral liquid agent contains $\underline{Kakkon-To}$ extract and Stevia Rebaudiana Bertoni, Compositae.

The plant is preferably blended as an extract containing ? 1 of stevioside, $\ensuremath{\text{c}}$

rebaudioside A, dulcoside A and B, rebaudeoside E, D and B,

steviolbioside and

stebiol or an enzymatically or chemically processed product of the stevia

extract, especially rebaudeoside A. The blend ratio of the plant is $5-100~\mathrm{mg}$

per 30 ml agent. The <u>Kakkon-To</u> to stevia blend wt. ratio is pref. 100:1-3500:1. The agent optionally contains ? 1 of antipyretics, analgesics,

bronchodilators, antitussives, expectorants, anti-choline agents, antihistaminic agents, anti-allergic agents, anti-inflammatory agents,

caffeines, vitamins, other crude drugs and antiacids.

USE - The agent is used to treat initial symptoms of a cold.

ADVANTAGE – The agent improves the characteristic bad taste of ${\bf Kakkon-To}$.

TITLE-TERMS: ORAL LIQUID AGENT TREAT COLD SYMPTOM CONTAIN EXTRACT STEVIA

REBAUDIANA BERTONI COMPOSITAE

DERWENT-CLASS: B04

CPI-CODES: B04-A08; B04-A10; B12-M07;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

H4 H405 H484 H8 M280 M315 M321 M332 M344 M383

M391 M416 M431 M620 M782 P422

Specific Compounds

R03440

Registry Numbers

95816

Chemical Indexing M2 *02*

Fragmentation Code

F012 F013 F014 F015 F016 F019 F123 F199 G031 G038

G039 G060 G810 H4 H405 H424 H484 H5 H523 H7

H720 H8 J0 J011 J2 J221 K0 L8 L814 L819

L823 L831 L833 M1 M126 M129 M141 M149 M210 M211

M240 M282 M311 M323 M341 M342 M373 M393 M413 M431

M510 M523 M530 M541 M782 P422

Ring Index Numbers

04804

Specific Compounds

R04090

Registry Numbers

130015

Chemical Indexing M2 *03*

Fragmentation Code

F012 F013 F014 F015 F016 F019 F123 F199 G031 G038

G039 G060 G810 H4 H405 H424 H483 H5 H522 H7

H720 H8 J0 J011 J2 J221 K0 L8 L814 L819

L821 L822 L831 M1 M126 M129 M136 M141 M149 M210

M211 M240 M282 M311 M323 M341 M342 M373 M393 M413

M431 M510 M523 M530 M541 M782 P422

Ring Index Numbers

04804

Specific Compounds

R00409

Registry Numbers

107822

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0409U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: 1998-012281